Search Results - "Piette, Fanny"

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98 by LOI, Sherene, SIRTAINE, Nicolas, DE AZAMBUJA, Evandro, QUINAUX, Emmanuel, DI LEO, Angelo, MICHIELS, Stefan, PICCART, Martine J, SOTIRIOU, Christos, PIETTE, Fanny, SALGADO, Roberto, VIALE, Giuseppe, VAN EENOO, Françoise, ROUAS, Ghizlane, FRANCIS, Prudence, CROWN, John P. A, HITRE, Erika

“…Previous preclinical and clinical data suggest that the immune system influences prognosis and response to chemotherapy (CT); however, clinical relevance has…”
Get full text

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data by Leo, Angelo Di, Dr, Desmedt, Christine, PhD, Bartlett, John M S, Prof, Piette, Fanny, PhD, Ejlertsen, Bent, MD, Pritchard, Kathleen I, Prof, Larsimont, Denis, MD, Poole, Christopher, Prof, Isola, Jorma, Prof, Earl, Helena, Prof, Mouridsen, Henning, MD, O'Malley, Frances P, MD, Cardoso, Fatima, MD, Tanner, Minna, MD, Munro, Alison, PhD, Twelves, Chris J, Prof, Sotiriou, Christos, MD, Shepherd, Lois, MD, Cameron, David, Prof, Piccart, Martine J, Prof, Buyse, Marc, PhD

“…Summary Background Prediction of response to anthracycline-based therapy for breast cancer is challenging. We aimed to assess the value of HER2 and TOP2A as…”
Get full text

Comparison of prognostic gene expression signatures for breast cancer by Haibe-Kains, Benjamin, Desmedt, Christine, Piette, Fanny, Buyse, Marc, Cardoso, Fatima, Van't Veer, Laura, Piccart, Martine, Bontempi, Gianluca, Sotiriou, Christos

“…During the last years, several groups have identified prognostic gene expression signatures with apparently similar performances. However, signatures were…”
Get full text

Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series by DESMEDT, Christine, PIETTE, Fanny, BERGH, Jonas, LIDEREAU, Rosette, ELLIS, Paul, HARRIS, Adrian L, KLIJN, Jan G. M, FOEKENS, John A, CARDOSO, Fatima, PICCART, Martine J, BUYSE, Marc, SOTIRIOU, Christos, LOI, Sherene, YIXIN WANG, LALLEMAND, Frangoise, HAIBE-KAINS, Benjamin, VIALE, Giuseppe, DELORENZI, Mauro, YI ZHANG, SAGHATCHIAN D'ASSIGNIES, Mahasti

“…Purpose: Recently, a 76-gene prognostic signature able to predict distant metastases in lymph node–negative (N − ) breast cancer patients was reported. The…”
Get full text

NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2 + breast cancer by Jacobs, Samuel A, Robidoux, André, Abraham, Jame, Pérez-Garcia, José Manuel, La Verde, Nicla, Orcutt, James M, Cazzaniga, Marina E, Piette, Fanny, Antolín, Silvia, Aguirre, Elena, Cortes, Javier, Llombart-Cussac, Antonio, Di Cosimo, Serena, Kim, Rim S, Feng, Huichen, Lipchik, Corey, Lucas, Peter C, Srinivasan, Ashok, Wang, Ying, Song, Nan, Gavin, Patrick G, Balousek, April D, Paik, Soonmyung, Allegra, Carmen J, Wolmark, Norman, Pogue-Geile, Katherine L

“…The primary aim of NSABP FB-7 was to determine the pathologic complete response (pCR) rate in locally advanced HER2-positive (HER2 ) breast cancer patients…”
Get full text

NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer by Jacobs, Samuel A, Wang, Ying, Abraham, Jame, Feng, Huichen, Montero, Alberto J, Lipchik, Corey, Finnigan, Melanie, Jankowitz, Rachel C, Salkeni, Mohamad A, Maley, Sai K, Puhalla, Shannon L, Piette, Fanny, Quinn, Katie, Chang, Kyle, Nagy, Rebecca J, Allegra, Carmen J, Vehec, Kelly, Wolmark, Norman, Lucas, Peter C, Srinivasan, Ashok, Pogue-Geile, Katherine L

“…We previously reported our phase Ib trial, testing the safety, tolerability, and efficacy of T-DM1 + neratinib in HER2-positive metastatic breast cancer…”
Get full text

Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer by Jacobs, Samuel A, Wang, Ying, Abraham, Jame, Feng, Huichen, Montero, Alberto J, Lipchik, Corey, Finnigan, Melanie, Jankowitz, Rachel C, Salkeni, Mohamad A, Maley, Sai K, Puhalla, Shannon L, Piette, Fanny, Quinn, Katie, Chang, Kyle, Nagy, Rebecca J, Allegra, Carmen J, Vehec, Kelly, Wolmark, Norman, Lucas, Peter C, Srinivasan, Ashok, Pogue-Geile, Katherine L

Get full text

Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer by Jacobs, Samuel A, Robidoux, André, Abraham, Jame, Pérez-Garcia, José Manuel, La Verde, Nicla, Orcutt, James M, Cazzaniga, Marina E, Piette, Fanny, Antolín, Silvia, Aguirre, Elena, Cortes, Javier, Llombart-Cussac, Antonio, Di Cosimo, Serena, Kim, Rim S, Feng, Huichen, Lipchik, Corey, Lucas, Peter C, Srinivasan, Ashok, Wang, Ying, Song, Nan, Gavin, Patrick G, Balousek, April D, Paik, Soonmyung, Allegra, Carmen J, Wolmark, Norman, Pogue-Geile, Katherine L

“…After the publication of this work [1] the authors have reported that in Table 3 The letter "T" in columns 5 and 7 should not be there…”
Get full text

Correlation Between Quantitative HER‐2 Protein Expression and Risk for Brain Metastases in HER‐2+ Advanced Breast Cancer Patients Receiving Trastuzumab‐Containing Therapy by Duchnowska, Renata, Biernat, Wojciech, Szostakiewicz, Barbara, Sperinde, Jeff, Piette, Fanny, Haddad, Mojgan, Paquet, Agnes, Lie, Yolanda, Czartoryska‐Arłukowicz, Bogumiła, Wysocki, Piotr, Jankowski, Tomasz, Radecka, Barbara, Foszczyńska‐Kłoda, Małgorzata, Litwiniuk, Maria, Dȩbska, Sylwia, Weidler, Jodi, Huang, Weidong, Buyse, Marc, Bates, Michael, Jassem, Jacek

“…Background. Patients with human epidermal growth factor receptor (HER)‐2+ breast cancer are at particularly high risk for brain metastases; however, the…”
Get full text

Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10 by Abraham, Jame, Montero, Albert J, Jankowitz, Rachel C, Salkeni, Mohamad Adham, Beumer, Jan H, Kiesel, Brian F, Piette, Fanny, Adamson, Laura M, Nagy, Rebecca J, Lanman, Richard B, Sperinde, Jeff, Huang, Weidong, Allegra, Carmen J, Srinivasan, Ashok, Wang, Ying, Pogue-Geile, Katherine L, Lucas, Peter C, Jacobs, Samuel A

“…Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer eventually develop resistance to dual-antibody therapy with…”
Get full text

Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer by Buyse, Marc, Loi, Sherene, van't Veer, Laura, Viale, Giuseppe, Delorenzi, Mauro, Glas, Annuska M., Saghatchian d'Assignies, Mahasti, Bergh, Jonas, Lidereau, Rosette, Ellis, Paul, Harris, Adrian, Bogaerts, Jan, Therasse, Patrick, Floore, Arno, Amakrane, Mohamed, Piette, Fanny, Rutgers, Emiel, Sotiriou, Christos, Cardoso, Fatima, Piccart, Martine J.

“…Background: A 70-gene signature was previously shown to have prognostic value in patients with node-negative breast cancer. Our goal was to validate the…”
Get full text

Neratinib-Plus-Cetuximab in Quadruple-WT ( KRAS, NRAS, BRAF, PIK3CA ) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study by Jacobs, Samuel A, Lee, James J, George, Thomas J, Wade, 3rd, James L, Stella, Philip J, Wang, Ding, Sama, Ashwin R, Piette, Fanny, Pogue-Geile, Katherine L, Kim, Rim S, Gavin, Patrick G, Lipchik, Corey, Feng, Huichen, Wang, Ying, Finnigan, Melanie, Kiesel, Brian F, Beumer, Jan H, Wolmark, Norman, Lucas, Peter C, Allegra, Carmen J, Srinivasan, Ashok

“…In metastatic colorectal cancer (mCRC), ( ) gene amplification is implicated in anti-EGFR therapy resistance. We sought to determine the recommended phase II…”
Get full text

Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types by Lonez, Caroline, Verma, Bikash, Hendlisz, Alain, Aftimos, Philippe, Awada, Ahmad, Van Den Neste, Eric, Catala, Gaetan, Machiels, Jean-Pascal H, Piette, Fanny, Brayer, Jason B, Sallman, David A, Kerre, Tessa, Odunsi, Kunle, Davila, Marco L, Gilham, David E, Lehmann, Frédéric F

“…IntroductionNKR-2 are autologous T cells genetically modified to express a chimeric antigen receptor (CAR) comprising a fusion of the natural killer group 2D…”
Get full text

Destructive Cleavage of Antigenic Peptides Either by the Immunoproteasome or by the Standard Proteasome Results in Differential Antigen Presentation by Chapiro, Jacques, Claverol, Stephane, Piette, Fanny, Ma, Wenbin, Stroobant, Vincent, Guillaume, Benoit, Gairin, Jean-Edouard, Morel, Sandra, Burlet-Schiltz, Odile, Monsarrat, Bernard, Boon, Thierry, Van den Eynde, Benoit J

“…The immunoproteasome (IP) is usually viewed as favoring the production of antigenic peptides presented by MHC class I molecules, mainly because of its higher…”
Get full text

Correlation Between Quantitative HER‐2 Protein Expression and Risk for Brain Metastases in HER‐2+ Advanced Breast Cancer Patients Receiving Trastuzumab‐Containing Therapy by Duchnowska, Renata, Biernat, Wojciech, Szostakiewicz, Barbara, Sperinde, Jeff, Piette, Fanny, Haddad, Mojgan, Paquet, Agnes, Lie, Yolanda, Czartoryska‐Arłukowicz, Bogumiła, Wysocki, Piotr, Jankowski, Tomasz, Radecka, Barbara, Foszczynska‐Kloda, Malgorzata, Litwiniuk, Maria, Dȩbska, Sylwia, Weidler, Jodi, Huang, Weidong, Buyse, Marc, Bates, Michael, Jassem, Jacek

Get full text

Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH by Desmedt, Christine, Sperinde, Jeff, Piette, Fanny, Huang, Weidong, Jin, Xueguang, Tan, Yuping, Durbecq, Virginie, Larsimont, Denis, Giuliani, Rosa, Chappey, Colombe, Buyse, Marc, Winslow, John, Piccart, Martine, Sotiriou, Christos, Petropoulos, Christos, Bates, Michael

“…The selection of patients with HER2-positive breast cancer for treatment with trastuzumab is based on the measurement of HER2 protein expression by…”
Get more information

Concurrent Bevacizumab with a Sequential Regimen of Doxorubicin and Cyclophosphamide Followed by Docetaxel and Capecitabine as Neoadjuvant Therapy for HER2− Locally Advanced Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group by Rastogi, Priya, Buyse, Marc E, Swain, Sandra M, Jacobs, Samuel A, Robidoux, André, Liepman, Marcia K, Pajon, Eduardo R, Dy, Philip A, Posada, Juan G, Melnik, Marianne K, Piette, Fanny, Geyer, Charles E, Mamounas, Elfetherios P, Wolmark, Norman

“…Abstract Background Bevacizumab with chemotherapy improves outcomes in patients with metastatic breast cancer (MBC). The purpose of this trial was to determine…”
Get full text

Unrelated Donor Status and High Donor Age Independently Affect Immunologic Recovery after Nonmyeloablative Conditioning by Baron, Frédéric, Storer, Barry, Maris, Michael B., Storek, Jan, Piette, Fanny, Metcalf, Monja, White, Kristen, Sandmaier, Brenda M., Maloney, David G., Storb, Rainer, Boeckh, Michael

“…The risk of cytomegalovirus (CMV) infection is higher after HLA-matched unrelated donor (URD) than after HLA-matched related donor (MRD) nonmyeloablative…”
Get full text